title: Oral administration of coenzyme Q₁₀ reduces MPTP-induced loss of dopaminergic nerve terminals in the striatum in mice.
abstract: The neuroprotective effect of coenzyme Q(10) (CoQ(10)) has been reported in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. In this study, we investigated whether oral administration of CoQ(10) could protect the striatal dopaminergic (DAergic) nerve terminals against MPTP-induced toxicity in C57BL/6N mice using immunoisolation technique for DAergic synaptosomes. CoQ(10) significantly attenuated decrease in dopamine transporter as well as in synaptophysin and actin protein levels in DAergic synaptosomes from MPTP-treated mice. The effect of CoQ(10) was also observed in crude synaptosomes fraction, but not in homogenate. Our results indicate that the nerve terminals are a site for the action of CoQ(10) against the MPTP-induced DAergic neurodegeneration.
authors: Department of Alternative Medicine and Experimental Therapeutics, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Ishikawa 920-1181, Japan.
authors: Shota
authors: S
authors: Kobayashi
authors: Akiko
authors: A
authors: Muroyama
authors: Hiroaki
authors: H
authors: Matsushima
authors: Ikuo
authors: I
authors: Yoshimura
authors: Yasuhide
authors: Y
authors: Mitsumoto
references: Brain Res. 1997 Feb 21;749(1):44-52
references: 9070626
references: Neurosci Res. 2011 Apr;69(4):352-5
references: 21185886
references: Neurobiol Dis. 2005 Apr;18(3):618-27
references: 15755687
references: Biochem Biophys Res Commun. 1998 Jul 30;248(3):660-3
references: 9703982
references: J Neurochem. 2008 Mar;104(6):1613-21
references: 17973981
references: Exp Neurol. 2003 Jan;179(1):103-10
references: 12504872
references: Exp Neurol. 1995 Apr;132(2):279-83
references: 7789466
references: J Neurochem. 2005 Jun;93(5):1199-208
references: 15934940
references: J Int Med Res. 2009 Mar-Apr;37(2):455-63
references: 19383240
references: PLoS One. 2008 Feb 20;3(2):e1616
references: 18286173
references: Brain Res Mol Brain Res. 2005 Mar 24;134(1):57-66
references: 15790530
references: Neuroscience. 2003;122(3):617-26
references: 14622905
references: J Neurosci. 1995 Nov;15(11):7727-33
references: 7472523
references: Ann Neurol. 1989 Dec;26(6):719-23
references: 2557792
references: Nat Clin Pract Neurol. 2008 Nov;4(11):600-9
references: 18978800
references: Lancet. 1989 Jun 3;1(8649):1269
references: 2566813
references: Brain Res. 1998 Feb 2;783(1):109-14
references: 9479058
references: Biochem Biophys Res Commun. 1989 Sep 29;163(3):1450-5
references: 2551290
references: Immunopharmacology. 1998 Jun;39(3):167-80
references: 9754903
references: Neurosci Res. 2003 Jun;46(2):161-9
references: 12767479
references: J Am Coll Nutr. 2001 Dec;20(6):591-8
references: 11771674
references: Exp Neurol. 2006 Nov;202(1):93-9
references: 16806180
references: Neurosci Lett. 2009 Sep 29;463(1):22-5
references: 19638300
references: Ann Neurol. 1991 Oct;30(4):563-71
references: 1665052
references: Biofactors. 1999;9(2-4):261-6
references: 10416039
references: J Neurosci. 1996 Jan 15;16(2):436-47
references: 8551328
references: Mol Neurobiol. 2003 Dec;28(3):209-18
references: 14709785
references: Neuron. 2003 Sep 11;39(6):889-909
references: 12971891
references: Arch Neurol. 2002 Oct;59(10):1541-50
references: 12374491